<DOC>
	<DOC>NCT01864148</DOC>
	<brief_summary>The primary objective of the study is to evaluate the efficacy of BIIB033 in participants with active relapsing MS when used concurrently with Avonex. Secondary objectives of this study in this study population are to assess the safety, tolerability, and population PK of BIIB033 when used concurrently with Avonex</brief_summary>
	<brief_title>Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Key Diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) or onset of Secondary Progressive Multiple Sclerosis (SPMS) RRMS and SPMS subjects must have evidence of ongoing disease activity within 12 months of enrollment. All male and female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for at least 6 months after their last dose of study treatment Key A Multiple Sclerosis (MS) relapse that has occurred within the 90 days prior to Day 1/Baseline and/or the subject has not stabilized from a previous relapse prior to Screening Previous history of clinically significant disease. Plans to undergo elective major procedures/surgeries at any time during the study. Treatment with any investigational Multiple Sclerosis (MS) drugs within 3 weeks or 5 times the half life (whichever is longer) prior to Day 1/Baseline Relapsing Remitting Multiple Sclerosis (RRMS) subjects with any history of inadequate response to any approved interferon Î² preparation History of Human Immunodeficiency Virus (HIV), hepatitis C virus antibody, or hepatitis B virus History or evidence of drug or alcohol abuse within 2 years prior to Randomization Note: Other protocol defined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>58 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>